Evidence map›Paper›PMID 42840322›Full record

ArticleJournal of the Canadian Association of Gastroenterology2026

Evaluation of fecal microbiota, live (RBL) for the prevention of recurrent

Theodore Steiner, Thomas Louie, Dina Kao, Dan Smyth, Beth Guthmueller, Tracey Jason, Susan N Elliott, Shivam Srivastava, Christine Lee

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Canadian Association of Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03931941 (A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03931941 phase3completednot on this map

A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (Microbiota Suspension) in Subjects With Recurrent Clostridium Difficile Infection

TypeinterventionalSponsorRebiotix Inc.Ran2019 to 2023Enrolled793ConditionsClostridium Difficile Infection, Infection, Communicable DiseasesArmsRBX2660
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Theodore SteinerDivision of Infectious Diseases, Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC, V6T 1Z4, Canada.ORCID https://orcid.org/0000-0002-3136-6668
Thomas LouieDepartment of Microbiology, Immunology, and Infectious Diseases, University of Calgary, Calgary, AB, T2N 1N4, Canada.
Dina KaoDivision of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, AB, T6G 2R3, Canada.
Dan SmythDivision of Infectious Diseases, Department of Medicine, Dalhousie University, Halifax, NS, B3H 4R2, Canada.
Beth GuthmuellerGastroenterology and Microbiome, Clinical TA, Global Clinical and Translational Sciences, Ferring Pharmaceuticals, Inc., Parsippany, NJ 07054, United States.
Tracey JasonGastroenterology and Microbome, Canada Medical, Ferring Inc., North York, ON, M2J 5C1, Canada.
Susan N ElliottGastroenterology and Microbome, Canada Medical, Ferring Inc., North York, ON, M2J 5C1, Canada.
Shivam SrivastavaGlobal Biometrics, Statistical Operations, Ferring Pharmaceuticals A/S, 2770 Kastrup, Denmark.
Christine LeeDepartment of Pathology and Laboratory Medicine (UBC), University of Victoria, Victoria, BC, V8W 2A4, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Fecal microbiota, live (RBL) is a single-dose, broad consortium, microbiota-based product approved in the United States and Canada for preventing recurrent Methods: PUNCH CD3-OLS was a phase 3, open-label, multicenter study evaluating safety and effectiveness of RBL in adults, including those with comorbidities, with recurrent Results: Among 117 Canadian participants who received RBL, most were female and White, with a mean age of 61.3 years; 24.8% reported a first recurrence. The enrolling Conclusions: Safety and effectiveness outcomes in Canadian participants were consistent with those observed in the PUNCH CD3 randomized controlled trial population, supporting the use of RBL for prevention of recurrent ClinicalTrialsgov identifier: NCT03931941.

Indexed as

Canadian subgroupfecal microbiotalive (RBL)microbiota-based productPUNCH CD3-OLSrecurrent Clostridioides difficile infection

Identifiers

PMID42840322
PMCPMC13639365

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.